Page 1 Extracted Terms:
- AHA Scientific Statements  
- guidelines  
- antihypertensive agents  
- aspirin  
- atherosclerosis  
- atherosclerotic cardiovascular disease  
- atrial fibrillation  
- behavior modification  
- behavior therapy  
- blood cholesterol  
- blood pressure  
- body mass index  
- cardiovascular team‑based care  
- cardiovascular  
- cardiovascular disease  
- cholesterol  
- chronic kidney disease  
- coronary artery calcium score  
- coronary disease  
- coronary heart disease  
- cost  
- diet  
- dietary patterns  
- dietary fats  
- dietary sodium  
- dyslipidemia  
- e‑cigarettes  
- exercise  
- healthcare disparities  
- health services accessibility  
- heart failure  
- hypertension  
- LDL cholesterol  
- diabetes mellitus  
- lifestyle  
- lipids  
- measurement  
- myocardial infarction  
- nicotine  
- nonpharmacological treatment  
- nutrition  
- physical activity  
- prejudice  
- primary prevention  
- psychosocial deprivation  
- public health  
- quality indicators  
- quality measurement  
- risk assessment  
- risk-enhancing factors  
- risk factors  
- risk reduction  
- risk reduction discussion  
- risk treatment discussion  
- secondhand smoke  
- sleep  
- smoking  
- smoking cessation  
- social determinants of health  
- socioeconomic factors  
- statin therapy  
- systems of care  
- tobacco  
- tobacco smoke pollution  
- treatment adherence  
- treatment outcomes  
- type 2 diabetes mellitus  
- waist circumference  
- weight loss

Page 2 Extracted Terms:
Atherosclerotic cardiovascular disease (ASCVD)  
Heart failure  
Atrial fibrillation  
Statin therapy  
Aspirin use  
Antihypertensive therapy  
Low‑density lipoprotein cholesterol (LDL‑C)  
High‑density lipoprotein cholesterol (HDL‑C)  
Coronary artery calcium (CAC) scanning  
Blood pressure  
Hypertension  
Type 2 diabetes mellitus  
Metformin (first‑line therapy for diabetes)  
Sodium‑glucose cotransporter‑2 (SGLT2) inhibitor  
Glucagon‑like peptide‑1 (GLP‑1) receptor agonist  
Tobacco use (risk factor)  
Risk‑estimation for ASCVD (10‑year ASCVD risk score)  
Lifestyle modifications (diet, exercise)

Page 3 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Heart failure  
- Atrial fibrillation  
- Blood pressure (BP)  
- Lipid‑lowering medication  
- Diabetes medication  
- Aspirin therapy  
- Exercise / physical activity  
- Tobacco use / smoking cessation  
- Secondhand smoke exposure  
- Life’s Simple 7 (ideal cardiovascular health metrics)  
- Lifestyle optimization (diet, activity, tobacco avoidance)  
- Primary prevention of ASCVD  
- Risk factor optimization  
- Shared decision‑making  
- Team‑based care  
- Social determinants of health  
- Clinical guideline‑directed management  
- Diagnostic testing for cardiovascular disease  
- Pharmacological therapy for cardiovascular risk reduction  
- ACC/AHA primary‑prevention guidelines  
- Cardiovascular risk assessment  
- Lifestyle goal setting (dietary modification, exercise plans)  
- Healthcare cost burden of cardiovascular disease (>$200 billion US annually)

Page 4 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Primary prevention of CVD/ASCVD  
- ACC/AHA guideline (for cardiovascular prevention)  
- Risk assessment (for cardiovascular risk)  
- Diet (as a cardiovascular risk factor)  
- Exercise / physical activity (cardiovascular health)  
- Obesity  
- Weight loss  
- Type 2 diabetes mellitus (T2DM)  
- Blood cholesterol / lipid levels  
- Hypertension / high blood pressure (BP)  
- Smoking cessation  
- Aspirin use (for cardiovascular prevention)  
- Cardiovascular risk  
- Heart disease (general term)

Page 5 Extracted Terms:
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Stable angina  
- Unstable angina  
- Arterial revascularization  
- Stroke  
- Transient ischemic attack (TIA)  
- Peripheral arterial disease  
- Heart failure  
- Atrial fibrillation  
- Lifestyle factors: diet, exercise, physical activity  
- Obesity  
- Diabetes  
- Blood cholesterol  
- High blood pressure (BP)  
- Smoking  
- Aspirin use  
- Team‑based care  
- Shared decision‑making  
- Social determinants of health  
- Primary prevention  
- Cost and value of prevention  
- Class of Recommendation (COR)  
- Level of Evidence (LOE)

Page 6 Extracted Terms:
**Key heart‑disease related terms extracted**

- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary heart disease (CHD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Hypertension (high blood pressure) – includes systolic BP (SBP), diastolic BP (DBP)  
- Diabetes mellitus (DM, specifically type 2 DM – T2DM)  
- Hyperlipidemia (high LDL‑C, low HDL‑C)  
- Pooled cohort equations (PCE) – ASCVD risk estimation  
- Glucagon‑like peptide‑1 receptor (GLP‑1R) agonists – cardiovascular benefit agents  
- Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors – cardiovascular benefit agents  
- Urinalysis markers: hemoglobin A1c (HbA1c) (used in diabetes control)  
- Agatston units (AU) – coronary calcium scoring  
- Risk‑factor control/optimization: lifestyle modification, pharmacologic therapy (statins, antihypertensives, antidiabetic drugs)  
- Team‑based care / multidisciplinary care (clinical strategy for ASCVD prevention)  
- Shared decision‑making (clinical decision process for preventive therapy)  

These terms capture the core disease entities, risk factors, biomarkers, therapeutic targets, and recommended clinical approaches discussed in the guideline.

Page 7 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiovascular risk assessment  
- Pooled Cohort Equations (PCE)  
- 10‑year ASCVD risk  
- Borderline risk (5 %–<7.5 %)  
- Intermediate risk (≥7.5 %–<20 %)  
- Risk‑enhancing factors  
- Statin therapy (primary prevention)  
- Coronary artery calcium (CAC) score  
- Traditional cardiovascular risk factors (e.g., age, sex, LDL‑C, HDL‑C, systolic BP, smoking)  
- Blood pressure (BP) / hypertension  
- Lipids / dyslipidemia  
- High blood pressure / hypertension management  
- Obesity / overweight  
- Weight loss / weight maintenance  
- Body‑size perception  
- Diabetes mellitus type 2  
- Glycemic control (HbA1c)  
- Lifestyle counseling (diet, exercise)  
- Diet modifications (low‑sodium, heart‑healthy)  
- Food access / food security  
- Physical activity / exercise prescription  
- Neighborhood environment / access to facilities  
- Sleep hygiene / short sleep duration (<6 h)  
- Tobacco use / tobacco treatment  
- Psychosocial stressors  
- Social support (individual and group)  
- Health literacy assessment  
- Socioeconomic status (SES)  
- Housing instability  
- Food insecurity  
- Transportation difficulties  
- Utility assistance needs  
- Interpersonal safety  
- Mental illness (comorbid)  
- Financial strain  
- Inadequate housing conditions  
- Inadequate social support  
- Exposure to adversity (violence, trauma)  
- Advanced age (≥75 y)  
- Racial/ethnic disparities in cardiovascular outcomes  
- Primary prevention of ASCVD  
- Cardiovascular outcomes  
- Social determinants of health (SDOH)  

These terms capture the key heart‑disease concepts, risk factors, interventions, and social determinants discussed in the guideline excerpt.

Page 8 Extracted Terms:
- ASCVD risk  
- Lifetime ASCVD risk  
- 10‑year ASCVD risk  
- 30‑year ASCVD risk  
- Primary prevention of cardiovascular disease  
- Lipid management  
- Blood‑pressure (BP) management  
- Stage 1 hypertension (BP 130–139/80–89 mm Hg)  
- Coronary artery calcium (CAC) score  
- Risk‑enhancing factors  
- Risk calculators (e.g., PCE, Framingham, Reynolds, SCORE, QRISK/JBS3)  
- PCE (Pooled Cohort Equations)  
- Framingham CVD risk score  
- Reynolds risk score  
- SCORE (Systematic Coronary Risk Evaluation)  
- QRISK / JBS3  
- Clinical decision support tools  
- Risk thresholds (low < 5 %, borderline 5 %–< 7.5 %, intermediate ≥ 7.5 %–< 20 %, high ≥ 20 %)  
- Statin therapy (e.g., for elevated ASCVD risk or familial hypercholesterolemia)  
- Familial hypercholesterolemia  
- Traditional cardiovascular risk factors  
- Race‑specific risk estimation (non‑Hispanic White, non‑Hispanic Black, other ethnic groups)  
- Age‑specific risk assessment (20–39 yrs, 40–59 yrs, 60–75 yrs, > 75 yrs)  
- Risk assessment frequency (every 4–6 years)  
- Lifestyle interventions (heart‑healthy lifestyle, diet, exercise)  
- Comorbidities (e.g., chronic inflammatory conditions, autoimmune disease, HIV infection, socioeconomic disadvantage)  
- Over‑ or underestimation of risk by PCE  
- Life expectancy considerations  
- Shared decision‑making in cardiovascular prevention



Page 9 Extracted Terms:
**Key terms related to heart disease**

- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiovascular disease (CVD)  
- Coronary artery calcium (CAC)  
- Coronary artery calcium score  
- Coronary atherosclerosis  
- Coronary artery calcium measurement  
- Coronary artery calcium score in Agatston units (AU)  
- Pooled Cohort Equation (PCE)  
- Risk calculators  
- Risk‑enhancing factors  
- Risk reclassification  
- Cardiovascular risk estimation  
- Cardiovascular risk stratification  
- Primary hypercholesterolemia  
- LDL‑cholesterol (LDL‑C)  
- HDL‑cholesterol (HDL‑C)  
- Non‑HDL‑cholesterol  
- Lipoprotein(a) [Lp(a)]  
- Apolipoprotein B (apoB)  
- High‑sensitivity C‑reactive protein (hs‑CRP)  
- Chronic kidney disease (CKD)  
- Chronic inflammatory disease  
- Rheumatoid arthritis (RA)  
- Systemic lupus erythematosus (lupus)  
- Human immunodeficiency virus (HIV)  
- Metabolic syndrome  
- Elevated triglycerides  
- Elevated blood pressure  
- Elevated glucose  
- Low HDL‑cholesterol  
- Diabetes mellitus  
- Ankle‑brachial index (ABI)  
- South Asian ancestry (high‑risk race/ethnicity)  
- Preeclampsia  
- Premature menopause (before age 40)  
- Early menopause (before age 55 in men, before age 65 in women)  
- Erectile dysfunction  
- Statin therapy  
- Aspirin (antiplatelet)  

These terms capture the principal concepts and risk‑enhancing factors discussed in the provided guideline excerpt.

Page 10 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted from the Text**

- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary artery calcium (CAC) score / measurement  
- Coronary heart disease (CHD)  
- Statin therapy / statins  
- Cholesterol (dietary & blood)  
- Lipid lowering therapy  
- Risk estimation tools (e.g., ASCVD Risk Estimator, PCE, 30‑year/lifetime risk estimator)  
- Risk reclassification & discrimination  
- Non‑calcified plaque  
- Lifetime ASCVD risk  
- 30‑year ASCVD risk  
- Cardiovascular mortality / deaths  
- Obesity epidemic  
- Diabetes mellitus  
- Hypertension  
- Lifestyle factors impacting cardiovascular risk  
- Nutrition and diet (heart‑healthy diet)  
- Vegetables, fruits, legumes, nuts, whole grains, fish  
- Saturated fat  
- Monounsaturated fat  
- Polyunsaturated fat  
- Trans fats  
- Dietary cholesterol  
- Sodium  
- Processed meats (e.g., bacon, salami, ham, hot dogs, sausage)  
- Refined carbohydrates  
- Sweetened beverages  
- Sugar and high‑carbohydrate diets  
- Low‑carbohydrate diets  
- Mediterranean diet  
- Plant‑based diet  

These terms encapsulate the primary concepts related to heart disease prevention, risk assessment, treatment, and lifestyle recommendations presented in the guideline excerpt.

Page 11 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Myocardial infarction (MI)  
- Stroke  
- Cardiovascular mortality / death  
- Heart disease  
- Coronary events / coronary artery disease  
- Blood pressure (BP) / Hypertension  
- Dietary sodium  
- Trans fatty acids  
- Saturated fatty acids  
- Unsaturated fatty acids  
- Dietary fats  
- Plant protein  
- Animal protein  
- Red meat  
- Processed red meat  
- Poultry  
- Fish  
- Dairy products  
- Eggs  
- Nuts and seeds  
- Mediterranean diet  
- DASH diet (Dietary Approaches to Stop Hypertension)  
- PREDIMED trial  
- PURE study (Prospective Urban Rural Epidemiology)  
- REGARDS study (REasons for Geographic and Racial Differences in Stroke)  
- ARIC study (Atherosclerosis Risk in Communities)  
- Type 2 diabetes mellitus (T2DM)  
- Sugar‑sweetened beverages  
- Artificially sweetened beverages  
- Added sugar  
- Low‑carbohydrate diet  
- Refined carbohydrates  
- Fried foods  
- Added fats  
- Organ meats  
- Low‑calorie sweetened beverages  

Page 12 Extracted Terms:
- ASCVD (Atherosclerotic Cardiovascular Disease)  
- Cardiovascular disease  
- Coronary heart disease  
- Myocardial infarction (MI)  
- Stroke  
- Endothelial dysfunction  
- Insulin resistance  
- Inflammation  
- Arrhythmias  
- Blood pressure (BP)  
- Hypertension  
- Lipids  
- Lipoproteins  
- LDL cholesterol  
- HDL cholesterol  
- Total cholesterol  
- Trans fat  
- Partially hydrogenated oils  
- High‑carbohydrate diet  
- Low‑carbohydrate diet  
- Animal protein (e.g., lamb, beef, pork, chicken)  
- Plant protein (e.g., nuts, whole‑grain breads)  
- Dietary fat  
- Dietary carbohydrate  
- Cardiovascular risk  
- Risk factors  
- Physical activity  
- Moderate‑intensity aerobic activity  
- Vigorous‑intensity aerobic activity  
- Sedentary behavior  
- Exercise guidelines (≥150 min/week moderate or ≥75 min/week vigorous)  
- Resistance exercise  
- Glycemic control  
- Diabetes  
- BP lowering  
- Cardiovascular health  
- Mortality rate  
- Mortality risk  
- Lifestyle counseling  
- Physical activity counseling  
- Aerobic exercise safety  
- Dose‑response relationship to ASCVD events and death.

Page 13 Extracted Terms:
ASCVD (atherosclerotic cardiovascular disease)  
Cardiovascular disease  
Heart failure  
Cardiometabolic risk factors  
Physical activity (general)  
Sedentary behavior  
Moderate‑intensity aerobic physical activity  
Vigorous‑intensity aerobic physical activity  
Light‑intensity physical activity  
Moderate‑to‑vigorous physical activity  
Physical activity intensity levels (METs) (e.g., 1.6–2.9 METs for light, 3.0–5.9 METs for moderate, ≥6 METs for vigorous)

Page 14 Extracted Terms:
- Cardiovascular disease  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Heart failure  
- Atrial fibrillation  
- Hypertension (high blood pressure)  
- Blood pressure (BP)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Triglycerides  
- Body mass index (BMI)  
- Waist circumference  
- Physical activity (exercise)  
- Weight loss (as prevention strategy)

Page 15 Extracted Terms:
- Cardiovascular disease  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiometabolic risk  
- Metabolic syndrome  
- Obesity  
- Overweight  
- Body mass index (BMI)  
- Waist circumference  
- Waist‑hip ratio  
- Dual‑energy X‑ray absorptiometry (DXA)  
- Bioimpedance  
- Type 2 diabetes mellitus (T2DM)  
- Glycemic control  
- Hemoglobin A1c (HbA1c)  
- Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitor  
- Glucagon‑like peptide‑1 receptor (GLP‑1R) agonist  
- Heart‑healthy dietary pattern  
- Mediterranean diet  
- DASH diet  
- Vegetarian/vegan diet  
- Physical activity  
- Moderate‑intensity physical activity  
- Vigorous‑intensity physical activity  
- Metformin  
- Cardiovascular risk factors  
- Weight loss  
- Central adiposity  
- ASCVD events  
- Cholesterol management  
- Hypertension  
- Cardiovascular risk factor treatment  
- Lifestyle interventions  
- Bariatric surgery  
- FDA‑approved drugs  
- National Heart, Lung, and Blood Institute (NHLBI)  
- Cardiovascular disease prevention guidelines  

Page 16 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- CVD events  
- CVD death  
- Primary prevention of cardiovascular disease  

Page 17 Extracted Terms:
**Terms related to heart disease extracted from the guideline text**

- ASCVD (atherothrombotic cardiovascular disease)  
- Cardiovascular disease (CVD)  
- Heart failure  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Coronary artery calcium score  
- Statin therapy  
- LDL‑C (low‑density lipoprotein cholesterol)  
- HDL‑C (high‑density lipoprotein cholesterol)  
- Total cholesterol  
- Hypercholesterolemia  
- Lipid‑lowering therapy  
- SGLT‑2 inhibitors  
- GLP‑1 receptor agonists  
- Glycemic control (diabetes mellitus) as a risk factor  
- Hypertension / high blood pressure  
- 10‑year ASCVD risk score  
- Primary prevention of CVD  
- Secondary prevention of CVD  
- Risk‑enhancing factors  
- Risk discussion / shared decision making  
- Intensive/statistically significant risk reduction  
- Cholesterol clinical practice guidelines  
- Clinical statements on ASCVD outcomes  
- Coronary artery calcium score thresholds (0, 1‑99, ≥100)  
- Intensive statin intensity (moderate‑intensity, high‑intensity)  
- Maximally tolerated statin therapy  

These terms collectively capture the key cardiovascular disease concepts and therapeutic considerations highlighted in the guideline excerpts.

Page 18 Extracted Terms:
Primary ASCVD prevention  
ASCVD risk factors  
Cholesterol management  
Low‑density lipoprotein cholesterol (LDL‑C)  
Statin treatment  
Statin safety  
Statin‑associated side effects  
Moderate‑intensity statin therapy  
High‑intensity statin therapy  
Randomized controlled trial (RCT)  
Cardiovascular risk factor  
Coronary artery calcium (CAC)  
Ankle‑brachial index (ABI)  
Apolipoprotein B (apoB)  
Lipoprotein(a) (Lp(a))  
High‑sensitivity C‑reactive protein (hs‑CRP)  
Coronary heart disease (CHD)  
Human immunodeficiency virus (HIV)  
Lifetime risk of ASCVD  
10‑year ASCVD risk  
Cardiovascular disease (CVD)  
Primary prevention  
Risk assessment  
Risk discussion  
Clinical trial  
Placebo comparison  
Ethnically and racially diverse population  
Intermediate‑risk patients  
Statin benefit  
Cardiovascular disease prevention policies

(Note: All terms are directly referenced or implied in the guideline text.)

Page 19 Extracted Terms:
**Key heart‑disease–related terms identified in the guideline excerpt**

1. ASCVD (atherosclerotic cardiovascular disease)  
2. Hard ASCVD endpoint  
3. LDL‑C (low‑density lipoprotein cholesterol)  
4. Statin therapy  
5. High‑intensity statin  
6. Moderate‑intensity statin  
7. Rosuvastatin  
8. Pravastatin  
9. JUPITER (Justification for the Use of Statins in Prevention) trial  
10. 10‑year ASCVD risk  
11. 20‑year ASCVD risk  
12. Cardiovascular mortality  
13. Cardiovascular death  
14. Myocardial infarction (MI)  
15. Coronary revascularization  
16. Primary prevention of cardiovascular disease  
17. Diabetes (type 1 and type 2)  
18. Diabetes‑related ASCVD risk  
19. Hypercholesterolemia (primary severe hypercholesterolemia)  
20. LDL‑C ≥ 190 mg/dL (≥ 4.9 mmol/L)  
21. High‑sensitivity C‑reactive protein (hsCRP)  
22. 7.5 % 10‑year risk threshold (PCE ≥ 7.5 %)  
23. High‑sensitivity CRP ≥ 2.0 mg/L  
24. Global risk  
25. Residual risk  
26. Risk‑enhancing factors (family history of premature ASCVD, elevated hsCRP, lipid‑rich environment)  
27. Lipid‑increasing effect of statins (LDL‑C lowering)  
28. Pooled Cohort Equations (PCE)  
29. Coronary event  
30. Cardiovascular event  

These terms capture the core concepts, risk measures, therapeutic strategies, and patient populations discussed in the cited ACC/AHA guideline for primary prevention of cardiovascular disease.

Page 20 Extracted Terms:
- ASCVD (atherosclerotic cardiovascular disease)  
- Cardiovascular disease  
- Heart disease  
- Primary prevention of cardiovascular disease  
- Statin therapy  
- Elevated lifetime ASCVD risk  
- Metabolic syndrome  
- Psoriasis  
- Rheumatoid arthritis  
- HIV  
- Protease inhibitors  
- Lipoprotein (a)  
- Triglycerides  
- Non‑HDL‑C (total cholesterol – HDL‑C)  
- Apolipoprotein B  
- Coronary artery calcium (CAC)  
- Coronary artery calcium score  
- CAC measurement  
- Risk reclassification  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Pooled Cohort Equations (PCE)  
- Diabetes mellitus (type 1 and type 2)  
- Diabetes‑specific risk enhancers:  
  - Long duration of diabetes (≥10 yr for T2DM; ≥20 yr for type 1)  
  - Albuminuria (≥30 µg albumin/mg creatinine)  
  - Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m²  
  - Retinopathy  
  - Neuropathy  
  - Ankle‑brachial index (ABI) < 0.9  
- Family history of premature ASCVD  
- Cigarette smoking  
- Chronic inflammatory conditions  
- Statin‑associated symptoms  
- Risk‑enhancing factors (e.g., elevated lipoprotein (a), metabolic syndrome, inflammatory diseases, HIV, protease inhibitors)

Page 21 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Antihypertensive medications  
- BP‑lowering medication  
- Nonpharmacological interventions  
- Weight loss  
- Heart‑healthy dietary pattern  
- Sodium reduction  
- Dietary potassium supplementation  
- Physical activity  
- Structured exercise program  
- Alcohol consumption  
- Primary prevention of cardiovascular disease  
- Cardiovascular disease (CVD)  
- Coronary heart disease  
- Stroke  
- Heart failure  
- Chronic kidney disease  
- Type 2 diabetes mellitus (T2DM)  
- 10‑year ASCVD risk  
- ACC/AHA pooled cohort equations  
- Meta‑analysis  
- Randomized controlled trials (RCTs)  
- Mortality (death from stroke, heart disease, or other vascular disease)  
- Modifiable risk factors  
- BP target (<130/80 mmHg)  
- ASCVD event risk


Page 22 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Primary prevention of cardiovascular disease  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- BP‑lowering medications  
- Antihypertensive drug treatment  
- Stroke  
- BP thresholds for treatment  
- Class of recommendation (clinical guideline)  
- Nonpharmacological interventions for hypertension  
- Weight loss / weight reduction  
- Healthy diet  
- DASH dietary pattern (Dietary Approaches to Stop Hypertension)  
- Dietary sodium reduction  
- Dietary potassium intake  
- Physical activity  
- Aerobic exercise  
- Dynamic resistance exercise  
- Isometric resistance exercise  
- Moderation of alcohol intake  
- Cardiovascular risk assessment  
- Normotension (normal blood pressure)

Page 23 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Coronary events  
- Stroke  
- Myocardial infarction (MI)  
- Cardiovascular mortality  
- Tobacco use  
- Smoking cessation 

Page 24 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary heart disease (CHD)  
- Myocardial infarction (MI)  
- Stroke  
- Cardiovascular disease (CVD)  
- Cardiovascular risk  
- Hypertension  
- Arrhythmias  
- Electronic nicotine delivery systems (ENDS) – cardiovascular risk  
- Cardiovascular and pulmonary diseases (combined term)

Page 25 Extracted Terms:
- Cardiovascular disease  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Heart failure  
- Myocardial infarction (MI)  
- Arrhythmia  
- Angina  
- Primary prevention  
- Cigarette smoking  
- Tobacco cessation  
- Tobacco dependence  
- Chronic disease management  
- Risk factor (tobacco use)  
- Premature death (associated with ASCVD)

Page 26 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Primary prevention of ASCVD  
- Secondary prevention of ASCVD  
- Low‑dose aspirin (75–100 mg daily)  
- Aspirin contraindication (increased bleeding risk)  
- Myocardial infarction (MI)  
- Stroke  
- Atherothrombosis  
- Platelet inhibition (irreversible)  
- Gastrointestinal bleeding  
- Peptic ulcer disease  
- Chronic kidney disease (CKD)  
- Thrombocytopenia  
- Coagulopathy  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Steroids  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Risk estimators (e.g., Pooled Cohort Equations – PCE)  
- 10‑year ASCVD risk threshold  
- Smoking restrictions in homes and vehicles  
- Second‑hand smoke exposure  
- Electronic nicotine delivery systems (ENDS)  
- Hazard–benefit ratio  
- Cardiovascular disease prevention guidelines (ACC/AHA, European guidelines)  
- Elevated ASCVD risk  
- Antithrombotic therapy  
- Coronary heart disease (implied by ASCVD context)

Page 27 Extracted Terms:
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Myocardial Infarction (MI)  
- Cardiovascular Disease (CVD)  
- Coronary Artery Calcium Score  
- Prophylactic Aspirin (low‑dose/high‑dose)  
- Bleeding Risk (including gastrointestinal bleeding)  
- Peptic Ulcer Disease  
- Thrombocytopenia  
- Coagulopathy  
- Chronic Kidney Disease (CKD)  
- Non‑steroidal Anti‑inflammatory Drugs (NSAIDs)  
- Steroids  
- Direct Oral Anticoagulants (DOACs)  
- Warfarin  
- Lipid Targets (LDL, HDL, triglycerides)  
- Blood‑Pressure (BP) Targets  
- Glucose Targets (HbA1c)  
- Family History of Premature MI  
- Risk‑Enhancing Factors  
- High‑Risk ASCVD  
- Low‑Risk ASCVD  
- Age (≥70 years, <40 years)  
- Body Weight (low‑weight vs high‑weight)  
- Risk‑Benefit Ratio of Aspirin  
- Cost‑Effectiveness / Value in Cardiovascular Care  

These terms capture the primary concepts related to heart disease addressed in the guideline excerpt.

Page 28 Extracted Terms:
- ASCVD (Atherosclerotic Cardiovascular Disease)  
- CVD (Cardiovascular Disease)  
- Coronary artery calcium measurement  
- Antihypertensive therapy  
- Statin therapy (cholesterol‑lowering therapy)  
- Primordial prevention  
- Primary prevention  
- Cardiovascular risk factors  
- Tobacco avoidance  
- Brisk physical activity  
- Healthy dietary pattern  
- Trans fats  
- Added sugars  
- Sugar‑sweetened beverages  
- Red meats  
- Sodium  
- Saturated fats  
- Lipid‑lowering medication  
- Risk‑enhancing factors  
- Quantitative risk estimation  
- Absolute risk of future ASCVD event  
- Cost‑effectiveness analysis  
- Quality‑adjusted life‑years (QALYs)  
- Social determinants of ASCVD risk  
- Health literacy  
- Lifestyle improvements (diet, exercise, smoking cessation)

Page 29 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- ASCVD (Atherosclerotic cardiovascular disease)
- Atherosclerotic cardiovascular disease prevention
- AHA (American Heart Association)
- ACC (American College of Cardiology)
- American College of Cardiology/American Heart Association (ACC/AHA) Guideline
- American College of Cardiology/American Heart Association Task Force
- Primary prevention of cardiovascular disease
- Cardiovascular disease
- Cardiovascular health
- Coronary heart disease
- Heart disease
- Hypertension
- Blood pressure
- High blood pressure
- Blood cholesterol
- Cholesterol management
- Lipid management
- Ideal cardiovascular health
- Risk factors for cardiovascular disease
- Mortality (cardiovascular mortality)
- Morbidity (cardiovascular morbidity)
- Behavioral risk factors
- Protective factors
- Patient‑centered approaches
- Comprehensive ASCVD prevention
- Team‑based care
- Pharmacist interventions in cardiovascular care
- Diabetes care (as a cardiovascular risk modifier)
- Class of recommendation
- Level of evidence
- Evidence‑based guidelines
- Clinical practice guidelines
- Systematic review
- Meta‑analysis
- Statin therapy (implicitly referenced in cholesterol management)

Page 30 Extracted Terms:
- Cardiovascular disease  
- Heart disease  
- Hypertension  
- Blood pressure  
- Blood pressure control  
- Blood pressure management  
- Atherosclerotic cardiovascular disease  
- Myocardial infarction  
- Stroke  
- Cardiometabolic disease  
- Coronary artery disease  
- Heart failure  
- Lipid management / Dyslipidemia  
- Cholesterol  
- LDL cholesterol  
- HDL cholesterol  
- Triglycerides  
- Hyperlipidemia  
- Prevention of cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Secondary prevention of cardiovascular disease  
- Cardiovascular risk  
- Cardiovascular risk assessment  
- Cardiovascular risk score  
- Atherosclerotic cardiovascular disease risk score  
- Framingham risk score  
- Risk factor modification  
- Lifestyle modification  
- Physical activity  
- Sedentary behavior  
- Dietary patterns  
- Obesity  
- Body mass index (BMI)  
- Overweight  
- Body size misperception  
- Sleep disturbances / sleep deficiency  
- Health literacy  
- Social determinants of health  
- Built environment  
- Neighborhood environment  
- Health disparities / health inequalities  
- Advanced practice providers  
- Team‑based care  
- Shared decision‑making  
- Patient activation  
- Medication adherence  
- Glycemic control (in type 2 diabetes)  
- Preventive cardiology  
- Clinical guidelines on cardiovascular disease  
- Lifestyle interventions for cardiovascular health  
- Cardiovascular disease outcomes  
- Cardiovascular disease prevention strategies  
- Cardiovascular disease risk reduction  

*(Listed as key terms relevant to heart disease extracted from the provided clinical guideline references.)*

Page 31 Extracted Terms:
- ACC/AHA  
- 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease  
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APH/ASPC/NLA/PCNA Guideline on Blood Cholesterol Management  
- 2013 ACC/AHA Guideline on Treatment of Blood Cholesterol  
- ASCVD (Atherosclerotic Cardiovascular Disease)  
- Cardiovascular disease (CVD)  
- Cardiovascular risk assessment  
- Coronary artery calcium (CAC) score  
- Coronary heart disease (CHD)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Angina pectoris  
- Atherosclerosis  
- Chronic disease risk behaviors  
- Lipids (total cholesterol, LDL, HDL, triglycerides)  
- Low‑density lipoprotein (LDL)  
- High‑density lipoprotein (HDL)  
- Non‑HDL cholesterol  
- C‑reactive protein (CRP)  
- Statins (e.g., rosuvastatin, atorvastatin)  
- Statin eligibility  
- Lifespan risk of cardiovascular disease  
- Lifetime risk of cardiovascular disease  
- 10‑year ASCVD risk calculator  
- Multi‑Ethnic Study of Atherosclerosis (MESA)  
- Framingham Risk Score  
- ESC guidelines (European Society of Cardiology)  
- Coronary artery calcium zero (CAC=0) as negative risk marker  
- Traditional cardiovascular risk factors  
- Family history of premature coronary heart disease  
- Pre‑eclampsia  
- Preterm delivery  
- Early menopause  
- Erectile dysfunction as a cardiovascular predictor  
- HIV infection and cardiovascular risk  
- Rheumatoid arthritis and cardiovascular events  
- Systemic lupus erythematosus (SLE) and myocardial infarction  
- Smoking cessation guidelines  
- Diabetes mellitus type 2 and cardiovascular risk  
- Glycaemic control  
- Insomnia and risk of cardiovascular disease  
- Social engagement and chronic disease risk  
- Psychological status and cardiovascular health  
- Multimorbidity  
- Risk prediction functions  
- Coronary artery calcium versus age in older adults  
- Negative risk markers (e.g., CAC=0)  
- Non‑traditional risk markers  
- Risk factor burden at age 50  
- Risk factor burden at age 70  
- Coronary artery calcium imaging  
- Cardiovascular health outcomes in astronauts (AstroCHARM)  
- Guideline‑based statin eligibility evaluation  
- Coronary artery calcium prevalence and prognostic implications  
- BioImage Study (personalized statin allocation)  
- Coronary artery calcium improvement of risk assessment  
- Coronary artery calcium score interpretation  
- Coronary calcification in low‑risk women  
- Coronatory artery calcium as a prognostic tool  
- Coronary calcium scoring in asymptomatic individuals  
- Coronary artery calcium and longevity  
- Coronary artery calcium in African American individuals  
- Coronary artery calcium in Asian Americans  
- Coronary artery calcium in different ethnicities  
- Cardiovascular disease risk calculators  
- ASCVD risk prediction models  
- Coronary artery calcium and statin therapy initiation  
- Coronary artery calcium and lifestyle preventive therapies  
- Coronary artery calcium and statin allocation  
- Coronary artery calcium as a determinant of future cardiovascular events  
- Cardiovascular disease outcomes in the Jackson Heart Study  
- Coronary artery calcium and treatment decisions  
- Cardiovascular health promotion series  
- Coronary artery calcium and clinical decision making.

Page 32 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Primary prevention of CVD  
- Secondary prevention of CVD  
- Cardiovascular risk prediction / risk assessment  
- Pooled cohort equations (ACC/AHA)  
- Framingham risk score / study  
- Reynolds risk score  
- European Society of Cardiology (ESC/EAS) guidelines  
- American College of Cardiology / American Heart Association (ACC/AHA) guidelines  
- Joint British Societies (JBS3) consensus  
- Canadian Cardiovascular Society dyslipidaemia guidelines  
- US Preventive Services Task Force recommendations (aspirin, statin use)  
- Statin therapy / statin prescribing  
- Aspirin use for primary prevention  
- Dyslipidemia management  
- Lipid goals (LDL‑C, HDL‑C, triglycerides)  
- Coronary artery calcium (CAC) scoring  
- Coronary artery calcium testing guidance  
- Hypertension / blood pressure management  
- Lifestyle modification (diet, exercise, smoking cessation)  
- Mediterranean diet (extra‑virgin olive oil, nuts)  
- Plant‑based diets  
- Diet quality (nutrient composition, fiber)  
- C‑reactive protein (CRP) as a risk marker  
- Risk factor clustering (age, sex, smoking, diabetes, hyperlipidemia, hypertension)  
- Socioeconomic position / social deprivation status  
- Race/ethnicity related risk variation  
- Gender‑specific risk models  
- Revascularization (PCI, CABG)  
- Global cardiovascular risk (e.g., Reynolds score)  
- Risk factor algorithms for specific populations (e.g., Veterans Affairs, Women’s Health Initiative, China‑PAR, Korean risk model)  
- Prevention strategies in specialty populations (rheumatoid arthritis, diabetes)  
- Cardiovascular outcomes (myocardial infarction, stroke, heart failure)  
- Clinical decision tools (e.g., clinical risk calculators, calculators embedded in electronic health records)  
- Risk prediction performance (validity, calibration, discrimination)  
- Risk score recalibration / customization  
- Evidence‑based guideline implementation  
- Prevention of cardiovascular disease in adults  

These terms capture the key concepts related to heart disease and cardiovascular disease prevention and management that are referenced throughout the provided guideline citations.

Page 33 Extracted Terms:
- Heart disease  
- Cardiovascular disease  
- Coronary heart disease  
- Myocardial infarction  
- Stroke  
- Ischemic heart disease  
- Ischemic stroke  
- Cardiovascular mortality  
- Cardiometabolic health  
- Trans fatty acids (risk factor for heart disease)  
- Dietary sodium (risk factor for heart disease)  
- Added sugar (risk factor for heart disease)  
- Red and processed meat (risk factor for heart disease)  
- Long‑chain n‑3 polyunsaturated fatty acids (protective factor for heart disease)  
- Pro‑vegetarian food pattern (protective factor for heart disease)  

Page 34 Extracted Terms:
- Cardiovascular disease  
- Heart disease  
- Cardiovascular disease prevention  
- Coronary heart disease  
- Coronary artery disease  
- Stroke  
- Ischemic heart disease  
- Heart failure  
- Atrial fibrillation  
- Hypertension  
- Type 2 diabetes mellitus  
- Metabolic syndrome  
- Obesity  
- Overweight  
- Central obesity (waist circumference, waist‑hip ratio)  
- Body mass index (BMI)  
- Bariatric surgery (gastric bypass, sleeve gastrectomy, adjustable gastric banding)  
- Intensive lifestyle intervention (diet, exercise)  
- Physical activity  
- Aerobic training  
- Resistance training (strength training)  
- Isometric exercise  
- Sedentary behaviour  
- Subclinical coronary artery disease  
- Acute cardiovascular events  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cardiometabolic health  
- Cardiovascular disease risk factors  
- ACC/AHA primary‑prevention guidelines  
- European society of cardiology cardiovascular‑disease‑prevention guidelines  
- American Heart Association/ACC guidelines on obesity and overweight  
- WHO guidelines on body‑mass index for Asian populations  
- American Heart Association scientific statements on physical activity in health care settings  
- American Heart Association Council on nutritional, physical activity, and metabolism  
- American Heart Association Council on clinical cardiology  
- American Heart Association task force on practice guidelines  
- American College of Cardiology/Heart Association task force on obesity  
- American College of Cardiology/Heart Association task force on type 2 diabetes prevention  
- National Physical Activity Plan (American Heart Association)

Page 35 Extracted Terms:
- Cardiovascular disease  
- Coronary artery disease  
- Coronary heart disease  
- Cardiovascular risk  
- Cardiovascular outcomes  
- Heart disease  
- Stroke  
- Acute coronary events  
- Vascular events  
- High blood cholesterol  
- LDL cholesterol  
- Statin therapy  
- Rosuvastatin  
- Lovastatin  
- Simvastatin  
- Ezetimibe  
- Empagliflozin  
- Dapagliflozin  
- Canagliflozin  
- Liraglutide  
- Semaglutide  
- Albiglutide  
- GLP‑1 receptor agonist  
- C‑reactive protein

Page 36 Extracted Terms:
- Coronary artery calcium score  
- Statin therapy  
- Familial hypercholesterolemia  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Apolipoprotein B  
- Lipoprotein(a)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary heart disease (CHD)  
- Cardiovascular disease (CVD)  
- Primary prevention of cardiovascular disease  
- Cardiovascular risk assessment  
- Cardiovascular risk scores (e.g., Framingham, ACC/AHA)  
- High‑intensity statin therapy  
- Cholesterol‑lowering interventions  
- Metabolic syndrome  
- Type 2 diabetes mellitus  
- Type 1 diabetes mellitus  
- Myocardial infarction (MI)  
- Acute coronary syndrome (ACS)  
- Dyslipidemia  
- Elevated high‑sensitivity C‑reactive protein (hs‑CRP)  
- Psoriasis (as a cardiovascular risk factor)  
- Human immunodeficiency virus (HIV) (as a cardiovascular risk factor)  
- Coronary artery disease (CAD)  
- Coronary artery calcium (CAC) testing  
- Statin eligibility criteria  
- Coronary artery plaque  
- Lipid‑lowering agents (e.g., pravastatin, atorvastatin, rosuvastatin, simvastatin)  
- Coronary artery calcium reclassification  
- Cardiovascular event risk  
- Cardiovascular mortality  
- Risk discrimination  
- Risk calibration  
- Lifestyle preventive therapies  
- Calibrated risk scores  
- Clinical utility of genetic sequencing (e.g., FH genes)  
- Emerging lipid‑lowering therapies  
- Cardiovascular risk stratification in multi‑ethnic cohorts.

Page 37 Extracted Terms:
**Key heart‑disease related terms extracted from the provided text**

- Coronary artery disease  
- Cardiovascular disease (CVD)  
- Atherosclerosis  
- Coronar​ry artery calcium (CAC)  
- CAC score  
- Statin eligibility / statin therapy  
- Cholesterol / dyslipidemia  
- Primary prevention  
- Risk stratification  
- Non‑traditional risk markers  
- C‑reactive protein (CRP)  
- Family history of coronary heart disease  
- Coronary heart disease (CHD)  
- Myocardial infarction (MI)  
- Peripheral arterial disease (PAD)  
- Peripheral neuropathy  
- Diabetic retinopathy  
- Diabetes mellitus (type 2)  
- Albuminuria / renal function as CVD predictors  
- Stroke / cerebrovascular disease  
- Hypertension / high blood pressure  
- Sodium intake / sodium reduction  
- Potassium intake / potassium supplementation  
- DASH diet (Dietary Approaches to Stop Hypertension)  
- Exercise training / aerobic exercise  
- Isometric exercise training  
- Lifestyle modification  
- Weight loss / weight reduction  
- Blood pressure management  
- Clinical guidelines (ACC/AHA, ESC, AHA/ACC)  
- Trial of Hypertension Prevention (THP)  
- PREMIER trial  
- Global sodium consumption  
- Renin‑angiotensin‑aldosterone system (RAS) effects  
- Lipid profile (cholesterol, triglycerides)  

These terms capture the central concepts related to heart disease discussed in the cited guidelines and studies.

Page 38 Extracted Terms:
- Blood pressure  
- Hypertension  
- Systolic blood pressure  
- Diastolic blood pressure  
- Intensive blood pressure lowering  
- Standard blood pressure control  
- Antihypertensive treatment  
- Blood pressure lowering drugs  
- SPRINT study  
- ACC/AHA guideline  
- DASH diet  
- Exercise  
- Resistance training  
- Alcohol consumption  
- Alcohol reduction  
- Chronic kidney disease  
- Renal disease  
- Proteinuria  
- Protein restriction  
- Angiotensin‑converting enzyme inhibition  
- AASK trial  
- REIN‑2 trial  
- Type 2 diabetes mellitus  
- Diabetes  
- Left ventricular hypertrophy  
- Cardiovascular disease  
- Coronary heart disease  
- Cardiovascular risk  
- Metabolic risk  
- Lifestyle interventions  
- Diet  
- Weight loss  
- Metabolic syndrome  
- Hypercholesterolemia  
- Hyperlipidemia  
- Smoking  
- Physical activity  
- Lifestyle factors  
- Markov decision analysis  
- Meta‑analysis  
- Systematic review  
- Randomized controlled trial  
- Prospective study  
- Vascular mortality  
- Risk factor management  
- Blood pressure target  
- Microalbuminuria  
- Macroalbuminuria

Page 39 Extracted Terms:
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Blood pressure  
- Cardiovascular biomarkers  
- Hypertension  
- Cardiovascular risk  
- Cardiovascular risk assessment  
- Myocardial infarction  
- Stroke  
- Diabetes mellitus  
- Cardiovascular events  
- Heart failure  
- Coronary artery disease (implied)  
- Tobacco use  
- Smoking cessation  
- Electronic cigarettes  
- Cardiac sympathetic activity  
- Oxidative stress  
- DASH diet  
- Intensive blood‑pressure control  
- Intensive glucose lowering  
- Intensive blood‑pressure reduction  
- Blood‑pressure trajectories  
- Hypertension definition (Seventh Report/JNC7)  
- Cardiovascular disease prevention  
- Antihypertensive medication treatment  
- Intensive blood‑pressure reduction studies  
- Cardiovascular outcomes in diabetes  
- Cardiovascular risk with second‑hand smoke exposure  
- Cardiovascular risk in smokers  
- Cardiovascular risk in e‑cigarette users  

Page 40 Extracted Terms:
- Cardiovascular disease  
- Primary prevention  
- Aspirin  
- Bleeding risk  
- Coronary circulation  
- Cardiovascular events  
- Atherosclerosis / Atherosclerotic cardiovascular disease  
- Heart failure  
- Stroke  
- Peripheral arterial disease  
- Diabetes mellitus  
- Antithrombotic therapy  
- Low‑dose aspirin  
- High‑dose aspirin  
- Acute coronary events  
- Body weight / dose relationship  
- European Society of Cardiology guidelines  
- American Heart Association statements  
- American Diabetes Association position statement

Page 41 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Blood‑pressure control  
- Hypertension (HTN)  
- Intensive blood‑pressure management  
- Statin therapy / statin use  
- Coronary heart disease (CHD)  
- Stroke (cerebrovascular disease)  
- Vascular risk levels  
- Cardiovascular events  
- Lifestyle counseling  
- Behavioral counseling  
- Diet/healthy diet  
- Physical activity/exercise  
- Weight‑loss interventions  
- Obesity  
- Glucose control / abnormal glucose  
- Type 2 diabetes mellitus  
- Tobacco cessation  
- Aspirin (for primary prevention)  

These terms capture the key concepts related to heart disease and its prevention that appear in the provided guideline excerpts.

Page 42 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Cardiovascular  
- Coronary  
- Heart  
- Myocardial infarction (MI)  
- CVD (Cardiovascular Disease)  
- CHD (Coronary Heart Disease)  
- Cerebrovascular  
- Stroke  
- Microvascular  
- Mortality  
- Prevent*  
- Tobacco Use  
- Smoking / cigarette use  
- Electronic Cigarettes / e‑cigarettes / vape / vaping (ENDS)  
- Aspirin (acetylsalicylic acid)  
- Clopidogrel  
- Diet / Diet Therapy (healthy diet)  
- Obesity / Weight Loss (overweight)  
- Type 2 Diabetes Mellitus (diabetes, prediabetes, impaired glucose tolerance)  

These terms collectively capture disease entities, risk factors, preventive therapies, and related interventions discussed in the guideline.

Page 43 Extracted Terms:
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Coronary heart disease (CHD)  
- Atherosclerosis  
- Acute coronary syndrome (ACS)  
- Angina (stable, unstable)  
- Unstable angina  
- Myocardial infarction (MI)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation myocardial infarction (NSTEMI)  
- Cardiogenic shock  
- Myocardial stunning  
- No‑reflow phenomenon  
- Sudden cardiac death  
- Heart arrest  
- Stroke (cerebrovascular, brain infarction, brain‑stem infarction)  
- Cerebrovascular disease  
- Hypertension  
- Lipids  
- Cholesterol (hypercholesterolemia)  
- Diabetes mellitus  
- Obesity  
- Smoking  
- Aspirin (antiplatelet therapy)  
- Waist circumference (obesity marker)  
- Exercise & physical activity (modifiable risk factor)  

These terms capture the core diseases, syndromes, risk factors, and related interventions discussed in the guideline excerpts.

Page 44 Extracted Terms:
**Key terms related to heart disease**

- Cerebral Infarction  
- Myocardial ischemia  
- Dementia multi infarct  
- Infarction anterior cerebral artery  
- Infarction middle cerebral artery  
- Infarction posterior cerebral artery  
- Myocardial revascularization  
- Coronary artery bypass  
- Internal mammary coronary artery anastomosis  
- Angioplasty  
- Angioplasty transluminal percutaneous coronary  
- Heart failure (HF)  
- Hospitalization / rehospitalization  
- Atherectomy coronary  
- Coronary stent  
- CABG (coronary artery bypass graft)  
- Bypass grafts  
- Carotid pathology  
- Non‑coronary revascularization procedure  
- Carotid revascularization  
- Lower extremity revascularization  
- Percutaneous transluminal angioplasty (PTA)  
- Stent placement  
- Abdominal aortic aneurysm repair  
- AAA repair  
- Risk score  
- Coronary risk modification  
- Cardiovascular diseases (CVD)  
- Cardiovascular disease  
- Coronary disease  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- CHF / CHD  
- Cerebrovascular disorders  
- Dyspnea paroxysmal  
- Edema cardiac  
- Exercise test (Graded exercise test / GXT)  
- Lifestyle / exercise / training / walking  
- VO₂ max / maximal metabolic equivalent (METs)  
- Physical activity  
- Acute Coronary Syndrome (ACS)  
- Acute coronary syndromes  
- Angina unstable  
- Cardiogenic shock (shock)  
- Myocardial stunning  
- No‑reflow phenomenon  
- Cardiac arrest  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation myocardial infarction (NSTEMI)  
- Death / sudden cardiac arrest  
- Stroke  
- Brain infarction / brain stem infarctions  
- Lateral medullary syndrome  

Page 45 Extracted Terms:
- Cardiovascular diseases
- Cardiovascular OR CVD
- Cardiovascular disease
- Coronary disease
- coronary
- Coronary artery disease
- Myocardial infarction
- Heart failure
- CHF OR CHD
- Cerebrovascular disorders
- “dyspnea paroxysmal”
- “edema cardiac”
- physiopathology
- Non‑coronary revascularization procedure
- Carotid revascularization
- Lower extremity revascularization
- Percutaneous transluminal angioplasty
- Stent placement
- Abdominal aortic aneurysm repair
- AAA repair
- complications
- Event? OR outcome? OR episode?
- Risk score
- Coronary risk modification

Page 46 Extracted Terms:
**Key terms related to heart disease**

- ACC/AHA Guideline  
- Primary Prevention  
- Cardiovascular Disease (CVD)  
- Heart Disease  
- Prevention of Heart Disease  
- Cardiology  
- Preventive Cardiology  
- Cardiologist / Cardiologists  
- Cardiac  
- Cardiac Disease  
- Coronary Artery Disease (CAD)  
- Heart Failure  
- Hypertension  
- Dyslipidemia  
- Diabetes / Diabetes Mellitus  
- Statins  
- Blood Pressure (BP)  
- Lifestyle Modification  
- Physical Activity / Exercise  
- Smoking Cessation  
- Nutrition / Diet  
- Cardiovascular Risk Assessment  
- Risk Factors  
- Framingham Risk Score  
- ASCVD Risk Calculator  
- Lipid Management  
- Lipids  
- LDL‑C / LDL  
- HDL‑C / HDL  
- Triglycerides  
- Atherosclerosis  
- Plaque  
- Endothelial Function  
- Inflammation  
- Biomarkers (e.g., hs‑CRP)  
- Systolic Blood Pressure  
- Diastolic Blood Pressure  
- Blood Glucose / HbA1c  
- Weight Management / Obesity  
- Sleep Apnea  
- Mediterranean Diet  
- DASH Diet  
- Non‑invasive Imaging  
- Stress Test  
- Coronary CT Angiography  
- Echocardiography  
- Cardiac Catheterization  
- Heart Rate Control  
- β‑Blockers  
- ACE Inhibitors  
- Angiotensin‑Receptor Blockers (ARBs)  
- Calcium Channel Blockers  
- Antiplatelet Therapy (e.g., Aspirin, Clopidogrel)  
- PCSK9 Inhibitors  
- Bile Acid Sequestrants  
- Fibrates  
- Niacin  
- Lipoprotein(a) / Lp(a)  
- Apolipoprotein B  
- LDLR  
- Cardiovascular Risk Algorithm  
- Prevention Guidelines  
- Clinical Statements  
- Evidence Grade / Recommendation Level  
- Implementation Strategies  
- Physician Education / Patient Education  
- Shared Decision‑Making  
- Multidisciplinary Care  
- Cardiovascular Institute / Prevention Program  
- Quality Improvement / Performance Measures  
- Health Policy / Quality Metrics  


These terms capture the principal concepts and interventions associated with heart disease prevention and care as referenced throughout the guideline and author affiliations.

Page 47 Extracted Terms:
Cardiovascular disease  
Primary prevention of cardiovascular disease  
Cardiology  
Heart disease  
Cardiovascular risk  
Cardiovascular medications  
Cardiopulmonary arrest  
Out‑of‑hospital cardiovascular event  
ACC/AHA  
AHA  
Cleveland Heart Lab  
Tendyne  
Athersys  
Cardiovascular device  
Cardiovascular therapy  
Coronary artery disease  
Heart failure  
Myocardial infarction  
Arrhythmia  
Stroke  
Percutaneous coronary intervention (PCI)  
Coronary artery bypass grafting (CABG)  
Implantable cardioverter‑defibrillator (ICD)  
Cardiac resynchronization therapy (CRT)  
Transcatheter aortic valve replacement (TAVR)  
Heart valve replacement  
Cardiomyopathy  
Angina  
Hypertension  
Dyslipidemia  
Diabetes mellitus



Page 48 Extracted Terms:
- Cardiovascular Disease  
- Heart Disease  
- Heart Failure  
- Cardiac Electrophysiology  
- Primary Prevention of Cardiovascular Disease  
- Cardiovascular Prevention  
- Cardiology  
- Cardiovascular Medicine  
- ACC/AHA Guideline  
- American Heart Association  
- American College of Cardiology  
- Heart Failure Society of America  
- Cardiovascular Division  
- Cardiovascular Research  
- Cardiovascular Health  
- Cardiovascular Epidemiology  
- Cardiovascular Risk Factors  
- Cardiovascular Outcomes  
- Cardiovascular Management  
- Cardiovascular Screening  

Page 49 Extracted Terms:
- ACC/AHA  
- Primary Prevention  
- Cardiovascular Disease  
- Heart Disease  
- Cardiology  
- Cardiovascular Medicine  
- Cardiac Rehabilitation  
- Nuclear Cardiology  
- American Heart Association  
- American Society of Nuclear Cardiology  
- National Heart, Lung, and Blood Institute (NHLBI)  
- Cardiovascular Research  
- Cardiac Prevention  
- Cardiovascular Disease Prevention  
- Cardiac Rehabilitation and Prevention  
- Cardiovascular Health  
- Heart Failure (inferred from cardiology focus)

Page 50 Extracted Terms:
- Cardiovascular disease  
- Heart disease  
- Primary prevention of cardiovascular disease  
- ACC/AHA guideline  
- Cardiologic / cardiology  
- Cardiovascular disease prevention  
- Lipid disorders  
- LDL‑C (low‑density lipoprotein cholesterol)  
- Atherosclerosis  
- Lipid metabolomics  
- Advanced lipid disorders program  
- Cardiovascular disease fellowship program  
- Cardiovascular disease (in clinical statements and guidelines)

Page 51 Extracted Terms:
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Heart disease  
- Cardiovascular imaging  
- Cardiac computed tomography (Cardiac CT)  
- Preventive cardiology  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease  
- Cardiovascular computed tomography  
- Cardiac imaging modalities  
- Clinical statements and guidelines related to cardiovascular disease  
- Cardiovascular disease prevention  

These terms capture the key cardiovascular/heart disease concepts referenced in the provided text.

